KRAS and colorectal carcinoma: Then, an expanded assessment of KRAS mutational status to codons 59, 61, 117, and 146 broadened to NRAS and HRAS mutations, led to restricted prescription of the anti-EGFR moAbs to all-RAS wild-type CRC patients (10).